In vitro synthesis of recombinant heparan sulfate

$456,016R01FY2016HLNIH

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Paper 38265424 Paper 38260317 Paper 37995272 Paper 37723160 Paper 37614159 Paper 37546770 Paper 37275960 Paper 37034606 Paper 37014788 Paper 36649428 Paper 36239422 Paper 36173931 Paper 35420777 Paper 35417268 Paper 35137686 Paper 35107975 Paper 34355888 Paper 34351732 Paper 34179782 Paper 33658363 Paper 33580179 Paper 33482195 Paper 33057098 Paper 33026409 Paper 32753592 Paper 32737203 Paper 32724854 Paper 32681173 Paper 32636266 Paper 32542212 Paper 32198425 Paper 32188725 Paper 31942981 Paper 31692167 Paper 31608625 Paper 31573759 Paper 31010931 Paper 30870573 Paper 30720464 Paper 30670588 Paper 30559077 Paper 30301767 Paper 30254073 Paper 29960275 Paper 29934491 Paper 29793137 Paper 29684759 Paper 29573524 Paper 29568440 Paper 29116038 Paper 29111696 Paper 29099173 Paper 28938773 Paper 28878012 Paper 28770943 Paper 28752383 Paper 28731518 Paper 28578872 Paper 28543100 Paper 28340300 Paper 28322799 Paper 28151637 Paper 28106177 Paper 28103688 Paper 28091666 Paper 28031461 Paper 27543274 Paper 27447199 Paper 27412370 Paper 27287383 Paper 27281424 Paper 27185050 Paper 26924554 Paper 26908652 Paper 26731579 Paper 26709038 Paper 26601950 Paper 26574650 Paper 26555370 Paper 26219501 Paper 26213979 Paper 26121409 Paper 26115461 Paper 26066846 Paper 25931123 Paper 25817684 Paper 25218438 Paper 25197032 Paper 24960693 Paper 24909446 Paper 24770491 Paper 24697306 Paper 24626379 Paper 24563485 Paper 24561662 Paper 24372337 Paper 24326668 Paper 24271188 Paper 23929984 Paper 23835156

Abstract

DESCRIPTION (provided by applicant): The proposal is aimed to improve the pharmacological effects of low-molecular weight heparins (LMWH). This project is a collaborative effort of four research groups, including Dr. Jian Liu (University of North Carolina) Dr. Robert Linhardt (Rensselaer Polytechnic Institute), Dr. Edward Harris (University of Nebraska, Lincoln) and Dr. Jawed Fareed (Loyola University Medical Center). LWMH is a widely used anticoagulant drug to treat thrombotic disorders. The currently marketed LMWH drugs are a mixture of sulfated poly-/oligo-saccharides, which are vulnerable to contamination and batch-to-batch variability. We plan to synthesize structurally homogeneous LMWH to eliminate the structural heterogeneity. The new LMWH constructs should display consistent anticoagulant activity, improved sensitivity to protamine neutralization, and controlled metabolic pathway. The synthesis of homogeneous LMWH will be completed using a chemo enzymatic approach. The pharmacological effects of the products will be evaluated in mouse and primate models. The success of this project will optimize the structures of heparin-based drugs with improved safety and efficacy.

View original record on NIH RePORTER →